Table of Contents Show
The precision oncology sector in India has witnessed a significant milestone with 4baseCare announcing the successful closure of Rs 90 crore in its Series B funding round. This substantial investment, co-led by renowned investors Ashish Kacholia and Lashit Sanghvi, marks a pivotal moment for the Bengaluru based healthtech startup as it prepares to scale its operations globally.
Strategic Investment for Global Growth
The latest funding round, which also saw participation from existing investor Yali Capital, will primarily fuel 4baseCare’s ambitious expansion strategy. The company plans to establish hospital-linked genomics laboratories across multiple geographies, including India, the Middle East, Southeast Asia, Latin America, and Central Asia. This strategic approach aims to make advanced cancer diagnostics accessible to patients in clinical settings across emerging markets.
Advancing AI-Powered Precision Oncology
A significant portion of the capital will be directed toward enhancing OncoTwin, 4baseCare’s flagship artificial intelligence platform. This innovative solution serves as a clinical decision support system, empowering oncologists with data driven insights for personalized cancer treatment strategies. By analyzing genomic information alongside real world clinical outcomes, OncoTwin enables healthcare professionals to make more informed, confident treatment decisions.
The platform’s credibility received substantial validation through its selection for the prestigious MSK iHub program at Memorial Sloan Kettering Cancer Center in New York, demonstrating international recognition of its potential impact on cancer care.
Addressing Healthcare Disparities
What distinguishes 4baseCare in the competitive healthtech landscape is its commitment to developing population specific clinico genomic databases. By focusing on underrepresented patient groups, the company addresses a critical gap in oncology research and treatment. These specialized datasets enable more accurate diagnoses and effective treatment protocols tailored to diverse genetic backgrounds.
Leadership Perspective
Expressing enthusiasm about the investment, co-leads Kacholia and Sanghvi highlighted the company’s unique positioning in building a comprehensive genomics and AI-driven clinical intelligence platform. They emphasized that strong hospital partnerships position 4baseCare advantageously for scaling across emerging markets.
CEO Hitesh Goswami, who co-founded the company with Kshitij Rishi, articulated the company’s vision, stating that the funding will facilitate global expansion while transforming OncoTwin into a sophisticated platform that continuously learns from real world outcomes, ultimately supporting oncologists with faster, more reliable insights.
Looking Ahead
As 4baseCare embarks on this growth trajectory, the funding represents more than capital infusion, it signifies investor confidence in the company’s mission to democratize access to precision oncology. Through strategic partnerships with hospitals and continuous technological innovation, 4baseCare is well positioned to make meaningful contributions toward improving cancer treatment outcomes across underserved populations worldwide.
